As­traZeneca CEO So­ri­ot is over­see­ing a top ex­ec team over­haul in move to in­te­grate Med­Im­mune in a sweep­ing re­struc­tur­ing

As­traZeneca CEO Pas­cal So­ri­ot pos­es for a pho­to­graph fol­low­ing a tele­vi­sion in­ter­view late last year Bloomberg

EX­CLU­SIVE — The on­go­ing R&D re­or­ga­ni­za­tion at As­traZeneca is claim­ing a group of se­nior ex­ec­u­tives in the com­pa­ny’s US R&D or­ga­ni­za­tion as As­traZeneca ab­sorbs its big sub­sidiary Med­Im­mune in­to a new­ly re­vamped glob­al or­ga­ni­za­tion.

The phar­ma gi­ant is han­dling fresh ex­its from Bahi­ja Jal­lal’s se­nior lead­er­ship team at As­traZeneca’s Med­Im­mune sub­sidiary — up un­til her de­par­ture a few weeks ago to take the CEO’s job at Im­muno­core in the UK, sources fa­mil­iar with the lat­est moves tell me. More de­par­tures are ex­pect­ed. And cur­rent Med­Im­mune ex­ecs have been spread­ing the word that the sub­sidiary will soon end its 11-year run as a sep­a­rate or­ga­ni­za­tion as the com­pa­ny re­or­ga­nizes un­der two pre­vi­ous­ly an­nounced main R&D ban­ners, split­ting Med­Im­mune’s large mol­e­cule work be­tween two dis­ease-spe­cif­ic or­ga­ni­za­tions.

The re­or­ga­ni­za­tion has sparked in­tense ru­mors about which re­search groups will come out on top and which will be rel­e­gat­ed to the side­lines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER